Cases & Deals

  • Home
  • Practices
  • Celgene invests in and enters into strategic collaboration with NantBioScience

Share

Celgene invests in and enters into strategic collaboration with NantBioScience

January 2014

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation, a biopharmaceutical company, in connection with its purchase of $75 million of Series A Preferred Stock in a private placement by NantBioScience, a subsidiary of NantWorks, LLC and a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs. Celgene and NantBioScience concurrently entered into a strategic collaboration to advance research programs to benefit cancer patients in need of new therapeutic solutions.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.